MedTrace Logo

Fundus Camera Module for Early Detection of Alzheimer's Disease

NCT06841848 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2025-02-24

No results posted yet for this study

Summary

Alzheimer's Disease (AD) affects tens of millions of people just in Europe. It is typically detected in its late stage when irreversible damage has already occurred, and current treatments are mostly conservative or palliative. Here we developed a device performing high-resolution multispectral imaging of the eye fundus to detect AD in its early stage. After clinical testing, the proposed device has a high potential to become a method for routine population screening, as it is non-invasive and affordable. The possibility of AD detection in an early stage is crucial for developing a new pharmaceutical treatment that would dramatically improve the lives of millions and save the expenses connected to lifelong healthcare assistance to people with AD in later stages.

Conditions

  • Alzheimer Disease

Interventions

DIAGNOSTIC_TEST

Fundoscopic Exam

visualization of the retina using an ophthalmoscope

Sponsors & Collaborators

  • I.R.C.C.S. Fondazione Santa Lucia

    lead OTHER

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2025-12-31
Completion
2026-03-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06841848 on ClinicalTrials.gov